Crucell focuses on developing and marketing vaccines and antibodies against a range of infectious diseases. The Company currently has a product portfolio of vaccines against influenza, hepatitis A, hepatitis B and typhoid fever.
Vaccines play a vital role in protecting against disease and have contributed significantly to the improvement of global public health in the twentieth century. Smallpox was eradicated through the use of vaccines, and polio is well on its way to eradication. Significant developments include the introduction of combination vaccines and the development of new vaccine technologies that may advance vaccine development.
In 2009, Crucell’s vaccines were administered to a vast number of people worldwide, thereby preventing more than 3.6 million cases of infectious disease and over 819,000 deaths1 that would otherwise have occurred.
In this section, you will find information about Crucell’s vaccine products and comprehensive information about the diseases each of these vaccines is designed to prevent.
Currently we are combating twelve major infectious diseases with our range of marketed vaccines in the paediatric, travel and endemic and respiratory fields.
Paediatric:
| - | Fully liquid vaccine for protection against five important childhood diseases | |
| - | Recombinant hepatitis B vaccine | |
| - | Vaccine for protection against measles and rubella (all age groups) | |
| - | Low dosage unique aluminum-free hepatitis A vaccine (0.25ml) | |
Travel and Endemic:
| - | Aluminum-free hepatitis A vaccine | |
| - | Oral typhoid vaccine | |
| - |
Internationally licensed oral vaccine against cholera (and ETEC) | |
Respiratory:
| - | Virosomal adjuvanted influenza (all age groups) |
E-MAIL THIS PAGE
PRINT THIS PAGE